- Q4 2023 Phathom Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2024$9.09 (-6.58%)Earnings
- Phathom Pharmaceuticals Inc to Discuss The FDA Approval TranscriptNov 02, 2023
- Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Phathom Pharmaceuticals Inc Conference call on the PHALCON-EE Trial Results TranscriptOct 18, 2021
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2021
- Phathom Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Phathom Pharmaceuticals Inc Phase 3 PHALCON-HP Results Corporate Call TranscriptApr 29, 2021
- Phathom Pharmaceuticals Inc Corporate Analyst Meeting TranscriptDec 14, 2020
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Phathom Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2020
Phathom Pharmaceuticals Inc Conference call on the PHALCON-EE Trial Results Transcript
Ladies and gentlemen, thank you for standing by, and welcome to Phathom Pharmaceuticals Phase III PHALCON-EE top line trial results conference call. (Operator Instructions)
I would now like to hand the call over to Joe Hand. Thank you. Please go ahead, sir.
Good morning, and thank you for joining us. My name is Joe Hand, and I'm Phathom's Chief Administrative Officer. We're excited to discuss the results from our PHALCON-EE Phase III erosive esophagitis trial that we shared earlier and to answer questions you have regarding the data. At the end of today's presentation, we will hold a Q&A session with Terrie Curran, our President and Chief Executive Officer; Azmi Nabulsi, our Chief Operating Officer; Martin Gilligan, our Chief Commercial Officer; and Tom Harris, our Senior Vice President, Regulatory Affairs.
As a reminder, matters covered in today's presentation, including the accompanying slides, include forward-looking statements. Such statements involve risks and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)